This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Immunotherapy  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Christophe Antille, MD; Jean-Hilaire Saurat, MD; Jann Lübbe, MD

Arch Dermatol. 2004;140:457-460.

Background  Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.

Observations  Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid eczema, rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment.

Conclusions  Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous. A variety of factors, such as vasoactive properties of tacrolimus, proliferation of Demodex due to local immunosuppression, and the occlusive properties of the ointment, may be involved in the observed phenomena. Future studies are needed to identify individual risk factors.

From the Department of Dermatology, University Hospital, Geneva, Switzerland. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Focal Acne During Topical Tacrolimus Therapy for Vitiligo
Bakos and Bakos
Arch Dermatol 2007;143:1223-1224.
FULL TEXT  

Rosaceiform Dermatitis as a Complication of Treatment of Facial Seborrheic Dermatitis With 1% Pimecrolimus Cream
Gorman and White
Arch Dermatol 2005;141:1168-1168.
FULL TEXT  

Rosacea
Powell
NEJM 2005;352:793-803.
FULL TEXT  

Alcohol Intolerance and Facial Flushing in Patients Treated With Topical Tacrolimus
Milingou et al.
Arch Dermatol 2004;140:1542-1544.
FULL TEXT